Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2343 January 2025

APPLICANT (stamp or sticker acceptable)				sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:					First Names:	First Names:	
Name:					Surname:	Surname:	
Address:					DOB:	Address:	
					Address:		
Fax Number:						Fax Number:	
Ribociclib							
Initial application Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate)							
	Patient has unresectable locally advanced or metastatic breast cancer						
There is documentation confirming disease is hormone-receptor positive and HER2-negative					R2-negative		
				Patient has an ECOG perfo	rmance score of 0-2		
		and	or	Disease has relapsed	d or progressed during prior endocrine therapy		
				Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or without menstrual-potential state			
				and	received prior systemic endocrine treatment for meta	astatic disease	
				Patient comme	nced treatment with ribociclib in combination with an	endocrine partner prior to 1 July 2024	
					dence of progressive disease		
	or	and		Treatment to be used in cor	nbination with an endocrine partner		
		and [Patient has not received pri	or funded treatment with a CDK4/6 inhibitor		
		[Patient has an active Specia	al Authority approval for palbociclib		
		and [and	Patient has experienced a gtreatment discontinuation	grade 3 or 4 adverse reaction to palbociclib that cann	ot be managed by dose reductions and requires	
		and [Treatment must be used in	combination with an endocrine partner		
		and [There is no evidence of pro	gressive disease since initiation of palbociclib		
Renewal Current approval Number (if known):							
Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)							
Treatment must be used in combination with an endocrine partner							
	and						
	There is no evidence of progressive disease since initiation of ribociclib						

I confirm the above details are correct and that in signing this form I understand I may be audited.